NCT04802590 2026-03-04
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT06522386 2026-03-02
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03946878 2026-02-17
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03710772 2026-02-11
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03567876 2025-12-08
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT05529069 2025-10-24
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05951959 2025-10-21
TrAVeRse
AstraZeneca
Phase 2 Active not recruiting
NCT03834688 2025-08-11
PrE0405
PrECOG, LLC.
Phase 2 Completed
NCT04477486 2025-07-09
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
AbbVie
Phase 2 Completed
NCT05025423 2025-06-13
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT05910801 2024-11-18
V-MIND
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT04659044 2024-09-19
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Terminated
NCT06324994 2024-03-22
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
Dalian Medical University
Phase 2 Not yet recruiting
NCT02471391 2023-08-21
AIM
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT04990778 2022-03-10
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn